Abstract:
:Morphologic dysplasia is an important factor in diagnosis of myelodysplastic syndrome (MDS). However, the role of dysplasia is changing as new molecular genetic and genomic technologies take a more prominent place in diagnosis. This review discusses the role of morphology in the diagnosis of MDS and its interactions with cytogenetic and molecular testing. Recent changes in diagnostic criteria have attempted to standardize approaches to morphologic diagnosis of MDS, recognizing significant inter-observer variability in assessment of dysplasia. Definitive correlates between cytogenetic/molecular and morphologic findings have been described in only a small set of cases. However, these genetic and morphologic tools do play a complementary role in the diagnosis of both MDS and other myeloid neoplasms. Diagnosis of MDS requires a multi-factorial approach, utilizing both traditional morphologic as well as newer molecular genetic techniques. Understanding these tools, and the interplay between them, is crucial in the modern diagnosis of myeloid neoplasms.
journal_name
Curr Hematol Malig Repjournal_title
Current hematologic malignancy reportsauthors
Shaver AC,Seegmiller ACdoi
10.1007/s11899-017-0405-ysubject
Has Abstractpub_date
2017-10-01 00:00:00pages
448-454issue
5eissn
1558-8211issn
1558-822Xpii
10.1007/s11899-017-0405-yjournal_volume
12pub_type
杂志文章,评审abstract::The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0287-9
更新日期:2015-12-01 00:00:00
abstract::Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-009-0028-z
更新日期:2009-10-01 00:00:00
abstract::Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status an...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-017-0371-4
更新日期:2017-04-01 00:00:00
abstract:PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0445-y
更新日期:2018-06-01 00:00:00
abstract::Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as alkylators or nucleoside analogs are rapidly being replaced by combination reg...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-006-0006-7
更新日期:2006-12-01 00:00:00
abstract:PURPOSE OF REVIEW:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood. RECENT FINDINGS:TCF4 is a master regulator that drives donwstream transcriptional programs in ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0489-z
更新日期:2018-12-01 00:00:00
abstract::The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0290-1
更新日期:2015-12-01 00:00:00
abstract::In recent years, the treatment of multiple myeloma has undergone significant changes. The availability of novel agents bortezomib, thalidomide and lenalidomide considerably improved the outcome of patients. The advantages related to the use of novel agents have been shown in various studies in patients eligible and in...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-013-0177-y
更新日期:2013-12-01 00:00:00
abstract:PURPOSE OF REVIEW:Artificial intelligence (AI), and in particular its subcategory machine learning, is finding an increasing number of applications in medicine, driven in large part by an abundance of data and powerful, accessible tools that have made AI accessible to a larger circle of investigators. RECENT FINDINGS:...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00575-4
更新日期:2020-06-01 00:00:00
abstract:PURPOSE OF REVIEW:This article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma. RECENT FINDINGS:The clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1,...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0482-6
更新日期:2018-12-01 00:00:00
abstract:PURPOSE OF REVIEW:Social media has dramatically changed the access and exchange of information in healthcare and beyond. A variety of platforms and resources exist allowing blood and marrow transplant providers, researchers, and patients to interact. We review the adoption of social media by the transplantation communi...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0487-1
更新日期:2018-12-01 00:00:00
abstract::A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-013-0176-z
更新日期:2013-12-01 00:00:00
abstract::Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-012-0131-4
更新日期:2012-09-01 00:00:00
abstract::The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by gen...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-013-0184-z
更新日期:2013-12-01 00:00:00
abstract:PURPOSE OF REVIEW:There are limited treatment options for relapsed/refractory classical Hodgkin lymphoma (cHL) patients who progress on brentuximab vedotin and programmed death-1 inhibitors. Camidanlumab Tesirine (Cami) is a new agent that has shown activity in multiply relapsed/refractory cHL patients. In this review,...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-021-00604-w
更新日期:2021-01-25 00:00:00
abstract::Measuring the quality of care for patients with chronic cancers is difficult, especially for heterogeneous malignancies such as the myelodysplastic syndromes (MDS). Recent work suggests that improvements may be needed in the quality of diagnostic, treatment, and end-of-life care for patients with these syndromes. More...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-016-0343-0
更新日期:2016-12-01 00:00:00
abstract::Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0250-9
更新日期:2015-06-01 00:00:00
abstract::The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 %...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0273-2
更新日期:2015-09-01 00:00:00
abstract::The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. ...
journal_title:Current hematologic malignancy reports
pub_type: 已发布勘误
doi:10.1007/s11899-018-0488-0
更新日期:2019-02-01 00:00:00
abstract:PURPOSE OF REVIEW:Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). RECENT FIN...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00572-7
更新日期:2020-04-01 00:00:00
abstract:PURPOSE OF REVIEW:Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challe...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0449-7
更新日期:2018-06-01 00:00:00
abstract:PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00596-z
更新日期:2020-12-01 00:00:00
abstract::Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0283-0
更新日期:2015-12-01 00:00:00
abstract:PURPOSE OF REVIEW:Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond,...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0477-3
更新日期:2018-12-01 00:00:00
abstract::The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-012-0129-y
更新日期:2012-09-01 00:00:00
abstract::Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline bas...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章
doi:10.1007/s11899-014-0219-0
更新日期:2014-09-01 00:00:00
abstract::Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicat...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-014-0207-4
更新日期:2014-06-01 00:00:00
abstract::C. difficile infection (CDI), the most common cause of hospital-acquired diarrhea, is very frequent after hematopoietic stem cell transplantation (HSCT). Recent publications suggest it affects between 6 % and 20 % of HSCT recipients during the first year and is more common following allogeneic transplant (allo-HSCT). ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-013-0193-y
更新日期:2014-03-01 00:00:00
abstract::Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse. Therefore, the optimal postremission therapy for AML remains to be defined, and further improvements in treatment strategies are required. Clinical trials have dem...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-006-0021-8
更新日期:2006-06-01 00:00:00
abstract:PURPOSE OF REVIEW:Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. RECENT FINDINGS:Dedicated geriatric assessment tools can aid the clini...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0454-x
更新日期:2018-06-01 00:00:00